Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
59212-0702-12 59212-0702 Prednisolone Sodium Phosphate Orapred ODT 30.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 30, 2020 In Use
59212-0701-12 59212-0701 Prednisolone Sodium Phosphate Orapred ODT 15.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 30, 2020 In Use
59630-0702-48 59630-0702 Prednisolone Sodium Phosphate Orapred ODT 30.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 1, 2006 Aug 31, 2015 No Longer Used
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous Mar 18, 2022 In Use
00003-3734-13 00003-3734 Nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 8, 2017 In Use
00003-3772-11 00003-3772 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
00003-3756-14 00003-3756 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug 30, 2021 In Use
00003-3774-12 00003-3774 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
00003-6120-01 00003-6120 Nivolumab and hyaluronidase-nvhy OPDIVO QVANTIG 2000.0 U/mL, 120.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Subcutaneous Jan 2, 2025 In Use
00003-3120-01 00003-3120 Nivolumab and hyaluronidase-nvhy OPDIVO QVANTIG 2000.0 U/mL, 120.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Subcutaneous Nov 24, 2025 In Use
59572-0730-07 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec 18, 2020 In Use
59572-0740-14 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sep 1, 2020 In Use
59572-0730-14 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sep 1, 2020 In Use
59572-0740-07 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec 18, 2020 In Use
78206-0148-01 78206-0148 Ontruzant Ontruzant Immunotherapy Monoclonal Antibody HER2 Intravenous Jun 1, 2021 In Use
78206-0147-01 78206-0147 trastuzumab Ontruzant 150.0 mg/1 Immunotherapy Monoclonal Antibody HER2 Intravenous Jun 1, 2021 In Use
00006-5033-02 00006-5033 Trastuzumab Ontruzant 150.0 mg/1 Immunotherapy Monoclonal Antibody HER2 Intravenous Apr 15, 2020 Sep 30, 2023 No Longer Used
00006-5034-02 00006-5034 Ontruzant Ontruzant Immunotherapy Monoclonal Antibody HER2 Intravenous Apr 15, 2020 Sep 30, 2023 No Longer Used
62856-0603-01 62856-0603 Denileukin diftitox Ontak 150.0 ug/mL Immunotherapy Cytokine Interleukin-2 Intravenous Nov 1, 2013 Nov 1, 2013 No Longer Used
15054-0043-01 15054-0043 Irinotecan Hydrochloride Onivyde 4.3 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Oct 22, 2015 In Use
69171-0398-01 69171-0398 Irinotecan Hydrochloride Onivyde 4.3 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Oct 22, 2015 Sep 30, 2019 No Longer Used
80425-0473-01 80425-0473 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 29, 2024 In Use
63187-0065-90 63187-0065 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 1, 2014 In Use
58118-1459-06 58118-1459 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 25, 2007 Jun 26, 2017 No Longer Used
50268-0647-14 50268-0647 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sep 20, 2023 In Use

Found 12159 results — Export these results